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Cost-effectivenessa b s t r a c t
Background: RTS,S/AS01, the most advanced vaccine against malaria, is now undergoing pilot implemen-
tation in Malawi, Ghana, and Kenya where an estimated 360,000 children will be vaccinated each year. In
this study we evaluate RTS,S/AS01 alongside bed net use and estimate cost-effectiveness.
Methods: RTS,S/AS01 phase III trial and bed net prevalence data were used to determine the effect of vac-
cination in the urban/periurban and rural areas of Lilongwe, Malawi. Cost data were used to calculate the
cost-effectiveness of various interventions over three years.
Findings: Since bed nets reduce malaria incidence and homogeneous vaccine efficacy was assumed, par-
ticipants without bed nets received greater relative benefit from vaccination with RTS,S/AS01 than par-
ticipants with bed nets. Similarly, since malaria incidence in rural Lilongwe is higher than in urban
Lilongwe, the impact and cost-effectiveness of vaccine interventions is increased in rural areas. In rural
Lilongwe, we estimated that vaccinating one child without a bed net would prevent 259 (162 to
338) cases of malaria over three years, corresponding to a cost of $1008 (771 to 1613) per case averted.
Alternatively, vaccinating one child with a bed net would prevent 159 (087 to 257) cases, corresponding
to $1643 (1016 to 3006) per case averted. Providing RTS,S/AS01 to 30,000 children in rural Lilongwe
was estimated to cost $782,400 and to prevent 58,611 (35,778 to 82,932) cases of malaria over a
three-year period. Joint interventions providing both vaccination and bed nets (to those without them)
were estimated to prevent additional cases of malaria and to be similarly cost-effective, compared to
vaccine-only interventions.
Interpretation: To maximize malaria prevention, vaccination and bed net distribution programs could be
integrated.
Funding: Impacts of Environment, Host Genetics and Antigen Diversity on Malaria Vaccine Efficacy
(1R01AI137410-01)1. Background
In 2017, there were an estimated 219 (95% CI 203 to 262) mil-
lion cases of malaria, 92% of which were in Africa. An estimated
435 (95% CI 401 to 470) thousand malaria-related deaths occurred,
disproportionately in African children under five years of age [1].
These numbers are an improvement over 2010 estimates, but pro-
gress has stalled since 2015, particularly in high burden countries
[1].
The RTS,S/AS01 malaria vaccine underwent a phase III clinical
trial, spanning 11 study sites across seven countries, from 2009
to 2014 [2]. The vaccine consists of three baseline doses, with a
fourth dose given 18 months after the third dose [2]. Protective
efficacy, as calculated by one minus the incidence rate ratio (1-
IRR), of the vaccine among children 5–17 months old averaged
363% across sites and ranged from 220% to 746% depending on
geographic area [3]. The World Health Organization is selectively
implementing the vaccine at sites in Malawi, Ghana, and Kenya
where 360,000 children will be vaccinated per year, in total [2].
To evaluate whether large-scale implementation of RTS,S/AS01
in sub-Saharan Africa would be an effective use of resources, eight
critical questions were laid out, in an effort to guide future research
[4]. This analysis focuses on one of these critical questions:
whether RTS,S/AS01 is a cost-effective preventative measure in
conjunction with bed nets.
Bed nets, often treated with insecticides, are one of the key
interventions used to prevent malaria and they represent the prin-
cipal vector control strategy in Malawi [5,6]. Bed net use was ‘‘op-
timized” in the phase III trial, meaning each participant had access
to a bed net as part of the study design [3].
We used Phase III trial data to estimate the expected three-year
absolute reduction in malaria cases due to the four-dose RTS,S/
AS01 vaccine, for a child living in Lilongwe, Malawi. We also com-
pared the cost-effectiveness of various bed net/vaccine interven-
tion combinations. Though the phase III trial occurred primarily
in urban and periurban areas of Lilongwe district, we calculated
the effect of interventions in both urban and rural settings, as cur-
rent pilot implementation efforts are occurring in the rural areas of
Lilongwe district. These estimates complement existing literature
on RTS,S/AS01 vaccine efficacy, with estimates of the potential
impact and cost-effectiveness of vaccine interventions against
malaria in implementation settings.2. Methods
2.1. Data
The phase III RTS,S/AS01 trial in Lilongwe enrolled children aged
5–17 months (n = 783) and passively surveilled them for malaria
for 18 months, beginning after the administration of the three
baseline doses of RTS,S/AS01 or a control vaccine [3]. On the 18th
month of follow-up, a fourth dose was given to half of those who
received the three-dose baseline RTS,S/AS01 vaccine and a control
vaccine was given to the rest of the participants, and follow-up
continued afterwards for a median of 48 months in total [3]. We
considered follow-up time for up to an additional 18 months (up
to three years total) post-fourth-dose. All participants were tested
for malaria in months 18 and 30 of follow-up but were otherwise
passively surveilled [3]. An episode of clinical malaria was defined
as illness accompanied by an axillary temperature of at least
37.5 C and Plasmodium falciparum asexual parasitemia > 5000 par-
asites per mm3 measured by microscopy [3]. Insecticide-treated
bed nets were distributed by study staff to children at the time
of screening [3]. Bed net use data were collected using a concurrent
household ecological survey, unique to the Malawi trial site, where
a field worker observed whether a net was on a child’s bed up to
four times during the follow-up period. These visits were sched-
uled for every six months of follow-up during the first two years
but had great variability in terms of when they were conducted.
The outcome of interest was the count of malaria cases post bed
net measurement and before the subsequent measurement. We
only counted cases after bed net use was determined through
the ecological survey to mitigate the potential for reverse causation
[7]. An exception was made for the time between baseline and thefirst bed net measurement, where malaria cases were paired with
the first bed net measurement. This was done to avoid excluding
the beginning of follow-up.
Because up to four bed net measurements were taken, one can
think of each participant having up to four periods of follow-up,
corresponding to each bed net measurement. Additionally, partic-
ipants assigned to the four-dose vaccine group had the same treat-
ment as the three-dose vaccine group in the first 18 months, but a
different treatment in the second 18 months, as the fourth dose
was not given until the 18-month mark. The unit of analysis in this
study is each time interval corresponding to the same participant,
most recent ecological survey, and 18-month period (first vs. sec-
ond). Each participant can experience one of ten possible combina-
tions of exposures (first/second 18-month period AND control/
three-dose/four-dose vaccine AND yes/no bed net use) in each time
interval (Fig. 1). For example, one potential exposure is: no bed net
and the three-dose vaccine in the first 18 months. Note that partic-
ipants could not be exposed to the fourth dose of the vaccine if the
time interval occurred in the first 18 months.
An estimate of bed net use prevalence, from outside this
study, is necessary to calculate the vaccine average effect in
the general population. The 2011–2013 malaria transmission
intensity (MTI) study was an annual cross-sectional survey of
P. falciparum prevalence administered concurrently with the
phase III RTS,S/AS01 trial in each study site [8]. The survey
was implemented during the peak malaria season and enrolled
400 under-five-year-olds annually, from the same catchment
area of the phase III trial [8]. Subjects in the RTS,S/AS01 vaccine
trial were excluded from participation [8]. The survey included
individual-level bed net use for the previous night. The most
recent estimate of bed net use prevalence (825%) from 2013
was used in this analysis to generalize to modern interventions
in Lilongwe city [8]. The 2017 Malaria Indicator Survey (MIS)
was used to obtain an estimate of bed net use prevalence in
under-fives in rural Lilongwe (634%) in order to generalize
interventions to rural areas [4].
An analysis of data from the phase III trial, using a 2-
dimensional spatial spline, showed transmission intensities up to
152 cases per year in a population with no vaccination and a
95% bed net coverage in urban Lilongwe, with estimates tending
to be higher out the outskirts of the study area (Supplemental
Fig. 1) [9]. In our calculations, we used a transmission estimate
of 20 cases per year in rural Lilongwe for a population without
vaccination and bed net coverage. We expect this estimate to be
conservative, given the protective nature of bed nets and increased
rurality, but we also included graphs allowing transmission inten-
sity to vary between 10 to 30 cases per year in the no bed net, no
vaccine (NBNV) group.
The RTS,S/AS01 vaccine was assumed to cost US$26.08 for the
four-dose regimen and bed nets were assumed to cost $220 per
net per year, based on estimates used for prior cost-effectiveness
analyses [10,11]. The cost estimate for the four-dose vaccine
includes the direct cost of the vaccine doses ($20) and indirect
costs such as wastage, freight, and insurance [10].2.2. Bednets and generalizability of the vaccine effect
Whether or not an individual used an owned bed net can be said
to be determined by a set of unknown variables, U. Since children
vaccinated with RTS,S/AS01 represent a random sample of children
usually attending Expanded Programme on Immunization (EPI)
visits, the distribution of U should be the same in the study and tar-
get populations [12]. By conditioning on bed net use in the trial, we
assumed that we accounted for the increased bed net access and
thus for being enrolled in the trial [13].
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Fig. 1. Potential Exposure Combinations in Each Time Interval of Follow-up During the First and Second 18 Months of the Phase III Trial of RTS,S/AS01.2.3. Model
We required a model which incorporated all ten of the possible
vaccine and bed net usage combinations (Fig. 1) while excluding
the two which could not have occurred. Furthermore, the three-
dose and four-dose vaccine groups must have the same treatment
effect in the first 18 months and different effects in the second
18 months. The desired model is specified below:
log E½Yij
 
¼ aþ bi þ b1Wij þ b2½ðAi þ BiÞ  ð1 PijÞ þ b3Pij
þ b4ðAi  PijÞ þ b5ðBi  PijÞ þ logðTijÞ; bi Nð0;r2Þ
We fit a generalized mixed effects Poisson model in R version
3.5.1 using the ‘‘lme4” package [14,15]. We used a log-link, a ran-
dom effect for each participant (biÞ to account for within-subject
correlation due to repeated measures, and a time (days) offset,
Tij. Yij is the number of malaria cases experienced by participant
i, during period j. Wij is one if participant i used a bed net during
period j and zero otherwise. Ai is one if participant i received the
three-dose RTS,S/AS01 vaccine at baseline and a control vaccine
at 18 months and zero otherwise. Bi is one if participant i received
the three-dose RTS,S/AS01 vaccine at baseline and the fourth dose
at 18 months and zero otherwise. Pij is zero if period j occurred
during the first 18 months of follow-up and one if period j occurred
during the second 18 months.2.4. Calculations
In calculations, the intercept taken from the model was
adjusted by r22 , where r
2 is the variance of the random intercept
[16]. Given that the model produces expected malaria counts per
day, 18-month counts for each bed net and treatment group were
calculated by multiplying the per-day estimate by 36525*15. Esti-
mates were obtained for the first and second 18 months, which
were combined to estimate malaria counts over three years in each
bed net and vaccine group.From these group means, we calculated the reduction in
malaria cases per person due to vaccination, conditional upon
whether the subject possessed a bed net or not. Using a cost esti-
mate, we calculated a cost per case averted by the vaccine for each
bed net group in urban Lilongwe. By altering the baseline transmis-
sion intensity in the NBNV group, we estimated the expected cases
averted and the cost per case averted by the vaccine for each bed
net group in rural Lilongwe. Using bed net prevalence estimates,
we then determined the number of malaria cases averted in the
first three years under a variety of interventions. Finally, we calcu-
lated the cost-effectiveness of these interventions.
We calculated confidence intervals with simulation-based
inference using the ‘‘arm” package by sampling 10,000 replicates
from the joint distribution of the parameter estimates (multivari-
ate normal) and selecting the 25th and 975th percentiles of sam-
pled estimates [17].
2.5. Sensitivity analysis
Malaria incidence at baseline may have influenced both bed net
use and malaria incidence over follow-up, introducing confounding
bias into the estimated effect of bed net use on malaria incidence.
Because some calculations use the estimated effect of bed net use
as a measure of the efficacy of bed nets, we evaluated background
malaria incidence as a confounder on the relationship between bed
net use and malaria. We applied the ‘‘mgcv” package, fitting a gen-
eralized additive model with a two-dimensional spatial spline of
malaria incidence as a random intercept [9].
3. Findings
3.1. Data characteristics and model results
Of the enrolled 783 children, 693 (89%) had bed net data
from at least one ecological survey and were included in this
analysis. There were 2128 bed net measurements in total over
four periods of follow-up corresponding to the four ecological
Table 1
Frequency of outcomes and exposures over the specified periods.
Period 1 (N = 693) Period 2 (N = 639) Period 3 (N = 522) Period 4 (N = 274) Overall (N = 2128)
Vaccine Group, N (proportion)
Control 227 (033) 210 (033) 180 (034) 91 (034) 708 (033)
Three-dose vaccine 241 (035) 215 (034) 164 (031) 91 (033) 711 (033)
Four-dose vaccine 225 (032) 214 (033) 178 (034) 92 (033) 709 (033)
Bed net use, N (proportion)
Yes 664 (096) 596 (093) 497 (095) 274 (100) 2031 (095)
No 29 (004) 43 (007) 25 (005) 0 (000) 97 (005)
Cases/time (days) 208/238,512 147/166,938 192/189,396 97/122,391 644/717,236
Cases per 18 months 048 048 056 043 049surveys (Table 1). A bed net was not observed in 97 instances, or
456% of observations. Bed net use remained consistent in peri-
ods 1 to 3, but in period 4 every single participant was observed
with a bed net. Participants had data from an average of 307 of
the four ecological surveys and 3954% had data from all four,
with similar distributions in each treatment group. A large pro-
portion of each treatment group was retained for the entire
three-year period and there was less loss to follow-up before
the 18-month mark in the four-dose vaccine group compared
to the other two groups (Fig. 2).
Where efficacy is defined as 1-IRR, we calculate that the RTS,S/
AS01 three-dose baseline vaccine is 5308% (95% CI 3619% toFig. 2. Violin Plots of Follow-up6550%) effective over an 18-month period and that bed net users
have a 3868% (95% CI 927% to 5856%) lower rate of malaria
(Table 2). We also find that the fourth dose of RTS,S/AS01 is
4308% (95% CI 1598% to 6144%) effective over 18 months. With-
out the fourth dose, the three-dose RTS,S/AS01 vaccine had an effi-
cacy of 1748% (95% CI 1808%, to 4233%) in the second
18 months of follow-up. If the observed reduction due to bed net
use can be considered to be an unbiased estimate of the true causal
effect, a combined intervention giving a bed net and the four-dose
RTS,S/AS01 vaccine is 7123% (95% CI 5266% to 8251%) effective
over the first 18 months and 6510% (95% CI 3936% to 7991%)
effective over the second 18-months.Time by Treatment Group.
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Intercept (a) 677 023 00012 No relevant interpretation16




076 016 047 The rate ratio of malaria cases per unit time in the three- and four-dose vaccine groups
versus the control group in the first 18 months




019 018 083 The rate ratio of malaria cases per unit time in the three-dose vaccine group versus the
control group in the second 18 months
Fourth dose, second
18 months (b5)
056 020 057 The rate ratio of malaria cases per unit time in the four-dose vaccine group versus the
control group in the second 18 months3.2. Calculations
‘‘Lilongwe Urban” estimates (Table 3) are computed using the
model parameters and describe single-participant, three-year
interventions. ‘‘Lilongwe Rural” estimates are computed in a simi-
lar manner, however, the transmission intensity in the NBNV group
was chosen to be fixed at 20 cases per year at baseline. Thus, con-
fidence intervals for the ‘‘Lilongwe Rural” estimates do not account
for uncertainty of this value. Over three years, in Lilongwe city,
vaccinating a child without a bed net prevented 109 (95% CI
053 to 193) cases of malaria corresponding to $2386 (1348 to
4895) per case averted. Vaccinating a child with a bed net pre-
vented 067 (95% CI 036 to 102) cases of malaria, corresponding
to $3891 (2555 to 7290) per case averted. More cases were pre-
vented by the vaccine in children without bed nets because chil-
dren without bed nets were expected to experience a higher
incidence of malaria. We assumed that the vaccine has the same
relative efficacy in all children, which leads to different numbers
of cases averted when baseline incidence differs between two
groups (i.e., children with and without bed nets). Due to a higher
incidence of malaria, compared to urban areas, vaccination in rural
areas would prevent additional cases of malaria and would be
more cost-effective: $1008 (771 to 1613) and $1643 (1016 to
3006) in children with and without bed nets, respectively.
As we cannot be confident that the chosen rate of 20 cases per
year in the NBNV group is the true baseline rate, we relaxed thisTable 3
Cost-Effectiveness in Urban and Rural Settings, First Three Years.
Cases per 3 person-years (95% CI) Cases
Lilongwe Urban
No bed net
No vaccine 224 (145 to 346) NA
Four-dose vaccine 115 (075 to 178) 109 (
Bed net
No vaccine 138 (111 to 171) NA
Four-dose vaccine 071 (057 to 088) 067 (
Lilongwe Rural
No bed net
No vaccine *531 (481 to 596) NA
Four-dose vaccine 272 (201 to 374) 259 (
Bed net
No vaccine 326 (215 to 491) NA
Four-dose vaccine 167 (101 to 277) 159 (
* The confidence interval only takes into account uncertainty in the reduction of the rat
in the base rate in the first 18 months.assumption, allowing the transmission intensity (cases per year)
in the NBNV group to vary between 10 and 30 cases and recal-
culating estimated cases averted due to vaccination and cost per
case averted (Fig. 3). Naturally, more cases are averted and the
cost per case averted decreases as transmission intensity rises.
We observe that the cost-effectiveness curves (bed net and no
bed net) trend towards convergence, as transmission intensity
increases.
We calculate the cost and impact of a variety of interventions
over the first three years of implementation (Table 4). These calcu-
lations assume bed net prevalences of 825% and 634% in urban
and rural Lilongwe [5,8]. Intervention 1 applies the vaccine effect,
stratified by bed net use and weighted by bed net prevalence, from
the trial to 30,000 people in urban Lilongwe. In interventions 2 and
3, bed nets are provided to vaccinated children who lack them,
with assumed usage rates of 100% and 50%, respectively. Interven-
tions 4, 5, and 6 correspond to interventions 1, 2, and 3 in rural
areas. The urban interventions carry a cost per case averted
between $33–35 while the rural interventions carry a cost per case
averted between $1150-1350. The cost per case averted does not
increase by providing bed nets to those who lack them, even at 50%
usage. We relaxed the assumption of 20 cases per year in the
NBNV group, allowing the transmission intensity (cases per year)
to vary between 10 and 30 cases and recalculating estimated
cases averted due to each intervention and cost per case averted
(Fig. 4). Here we see that adding bed nets to an intervention pre-averted per 3 person-years (95% CI) Cost per case averted (95% CI)
NA
053 to 193) $2386 (1348 to 4895)
NA
036 to 102) $3891 (2555 to 7290)
NA
162 to 338) $1008 (771 to 1613)
NA
087 to 257) $1643 (1016 to 3006)
e of malaria cases from the first 18 months to the second 18 months, not uncertainty
Fig. 3. Cases per Year (Transmission Intensity) in the No Bed Net, No Vaccine (NBNV) Group at Baseline versus Cases Averted and Cost per Case Averted. The dotted vertical line
represents the assumed rural incidence of 2 cases per year.
Table 4
Vaccine Implementation in 30,000 Children, First Three Years.
Intervention Bed nets given Number
Vaccinated
Total Cost ($) Cases Averted Cost per case averted ($)
With net No net
1) Lilongwe urban 0 24,750 5,250 782,400 22,325(11,956 to 34,474) 3505(2269 to 6540)
2) Lilongwe urban + bed nets(100% adoption) 5,250 30,000 0 817,050 24,661(14,022 to 37,466) 3313(2180 to 5826)
3) Lilongwe urban + bed nets(50% adoption) 5,250 27,375 2,625 817,050 23,492(13,147 to 35,961) 3478(2271 to 6209)
4) Lilongwe rural 0 19,020 10,980 782,400 58,611(35,778 to 82,932) 1335(943 to 2187)
5) Lilongwe rural + bed nets(100% adoption) 10,980 30,000 0 818,634 70,178(51,765 to 88,662) 1167(923 to 1581)
6) Lilongwe rural + bed nets(50% adoption) 10,980 24,525 5,490 818,634 64,395(44,292 to 85,740) 1271(954 to 1846)vents additional cases of malaria and remains similarly cost-
effective, regardless of the transmission intensities considered.
3.3. Sensitivity analysis
We fit a generalized additive model, identical in structure to the
model specified earlier in the methods section, except for the addi-
tion of a two-dimensional spatial spline as a random intercept. Our
main analysis found that bed net use was associated with a 3868%
(95% CI 927% to 5856%) reduction of malaria incidence while the
sensitivity analysis found that bed net use was associated with a
3464% (95% CI 087% to 5764%) reduction of malaria incidence.This model finds a combined intervention of the vaccine and bed
net use to be 6690% (95% CI 4480% to 8015%) effective in the first
18 months and 6568% (95% CI 3826% to 8093%) effective in the
second 18 months, comparable to the original estimates of
7123% (95% CI 5266% to 8251%) and 6510% (95% CI 3936%, to
7991%), respectively.4. Interpretation
By combining RTS,S/AS01 trial, bed net usage, bed net preva-
lence, and cost data, we estimated the effects of vaccination with
Fig. 4. Cases per Years (Transmission Intensity) in the No Bed Net, No Vaccine (NBNV) Group at Baseline versus Total Cases Averted and Cost per Case Averted in Each Three-
Year Rural Intervention. The dotted vertical line represents the assumed rural incidence of 2 cases per year in the control group.the RTS,S/AS01 vaccine alongside bed net use in Lilongwe, Malawi.
Assuming homogeneity of vaccine efficacy, the protective nature of
bed nets implies that vaccinating an individual with a bed net is
less cost-effective than vaccinating an individual without a bed
net. This is not to say that bed nets necessarily reduce the impor-
tance of the RTS,S/AS01 vaccine, or vice versa. In fact, our analysis
suggests that there is great potential to pair the two interventions.
An intervention pairing the RTS,S/AS01 vaccine and bed net distri-
bution is estimated to be 7123% (95% CI 4210% to 8570%) effec-
tive against clinical malaria in the first 18 months and 6510%
(95% CI 2377% to 8402%) effective in the second 18 months.
In a population of 30,000 with 634% bed net coverage and 2
malaria cases per year at baseline, we estimate pairing bed nets
with vaccine administration would prevent an additional 11,567
cases of malaria (20% increase over vaccination alone) over three
years and reduce the cost per case averted. Though it is not consid-
ered in this analysis, averting additional cases of malaria reduces
other costs: a systematic review found the median cost of diagnos-
ing a case of malaria was $4.32 and the median financial cost of
treating an episode of uncomplicated malaria was $5.84 [11]. This
median cost per uncomplicated case, $10.16, is only a few dollars
less than the cost per case averted of the rural interventions con-sidered. These results warrant investigation into the feasibility of
stockpiling bed nets at vaccination sites and distributing them to
uncovered individuals upon vaccination.
Even in a population where bed net coverage is high, the RTS,S/
AS01 vaccine has utility. Alone, the four-dose schedule prevents
5308% (95% CI 3619% to 6550%) of malaria cases over the first
18 months and 4308% (95% CI 1598% to 6144%) over the second
18 months. In children with bed nets, these point estimates corre-
spond to per-person estimates of 067 cases prevented over three
years in urban areas and 159 cases in rural areas.
4.1. Limitations
One major limitation is that the phase III trial was not a factorial
design and thus we cannot assume the estimated effect of bed net
use on malaria incidence to be the true causal effect. We assumed
this when we estimated the effect of combined bed net and vaccine
interventions using this data, thus those results (efficacies of the
combined interventions and interventions 2, 3, 5, and 6) must be
interpreted with caution. However, our sensitivity analysis found
little change in the reduction of malaria incidence due to bed net
use upon controlling for background incidence. Additionally, ran-
domized trials and other observational studies of bed nets have
found similar effects of bed nets on the incidence of malaria [18–
23]. Additionally, the indirect (herd) effects of the potential inter-
ventions were not considered. In the presence of an indirect effect,
these interventions would prevent additional cases of malaria and
cost less per case averted.
Furthermore, by omitting an interaction term between vaccina-
tion and bed net use and generalizing to rural settings, we have
assumed that the efficacy of RTS,S/AS01 does not vary by transmis-
sion intensity. A previous analysis done in Lilongwe, Malawi found
no evidence that vaccine efficacy varied by rainfall, which suggests
that transmission intensity does not influence the efficacy of RTS,S/
AS01 [24].
An additional limitation is our measurement of bed net use.
Though we include multiple bed net use measurements through-
out follow-up, each measurement serves as an imperfect proxy
for bed net use over a time period spanning multiple months and
thus could be subject to exposure misclassification.
4.2. Other relevant studies
Penny and Verity et al. predicts the median cost-effectiveness to
be $25 per case averted for the four-dose vaccine [10]. This is
somewhat different from our urban Lilongwe estimate of $3505
(2269 to 6540), though our interval contains their estimate. We
included 36 months of follow-up, where they included 32, and
our analysis was limited to Lilongwe where their analysis was
across all eleven phase III trial sites [10]. Furthermore, our analysis
accounted for bed net coverage.
Winskill et al. focused on the order in which a variety of inter-
ventions should be introduced [25]. Their model found that scaling
up bed net use to very high coverage was prioritized relative to
RTS,S/AS01 implementation [25]. They did not consider that the
two interventions could be implemented together, and that RTS,
S/AS01 vaccination might be a vehicle to achieving higher bed
net coverages. Another paper by Penny et al. found that vaccination
of 100,000 children with the three-dose vaccine would prevent
45,000 to 80,000 clinical cases of malaria in the first ten years of
implementation [26]. Galactionova et al estimated that between
66,491 and 104,933 cases would be averted in Malawi due to the
vaccination of 100,000 children [27]. Finally, Seo et al. followed a
‘‘hypothetical Malawian birth cohort” and compared bed nets
and RTS,S/AS01 interventions [28]. Their Markov model found that
the RTS,S/AS01 vaccine was more cost effective, however, they did
not consider vaccine efficacies below 496% [28].
These modeling studies have some advantages over our analysis
because they addressed waning vaccine efficacy as well as season-
ality or other factors which might influence the transmission
intensity of malaria. However, our study used longitudinal data
including individual-level bed net use, which separates our analy-
sis from the previous analyses. Additionally, our analysis focused
on a single country and therefore our analysis may provide a more
accurate picture for Malawi.
4.3. Conclusion
The current pilot implementation of RTS,S/AS01 will reduce
malaria cases across Malawi, Ghana, and Kenya and eventually in
other countries, if implemented. The Malawi site of the RTS,S/
AS01 trial was set in urban and periurban Lilongwe which has
lower malaria incidence than in rural areas. Thus, the present
implementation in rural areas should theoretically have a larger
per-person impact than the trial. Future programs could pair bed
net distribution with vaccine implementation, as the cost per case
averted remains stable at 50% adoption. Since children are already
traveling to clinics for vaccination, providing bed nets to vacci-nated children who lack them could be a logical and cost-
effective way to capitalize on the structure of vaccine implementa-
tion to prevent additional cases of malaria. Furthermore, provision
of bed nets together with RTS,S/AS01 might avoid a reduction of
bed net use after vaccination due to parents believing their kids
are protected. A factorial trial would help to build evidence for this
type of intervention.Statements, permissions
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